2226 GMT [Dow Jones]--Fisher & Paykel Healthcare gets a new bull in Jefferies following its FY 2025 result that showed growth across key divisions. Annual revenue rose by 16% on a year ago, with new app consumables up 20% and masks for treating sleep apnea up 14%. Gross margin expanded by 181 basis points. "With lead share, ongoing gains through clinical practice, further operating leverage and, as we see it, better placed with regard to tariffs, we move to Buy (from Hold)," says analyst Vanessa Thomson. Fisher & Paykel Healthcare is up 0.2% in early trading at NZ$35.07. (david.winning@wsj.com)
(END) Dow Jones Newswires
May 28, 2025 18:28 ET (22:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.